Updated: 14th September 2026
Reviewed by: David Small BSc (Hons), MSc, MTOPRA (Founder and CEO)
What Is Medical Device Sterilisation Validation?
Medical device sterilisation validation is the documented process used to demonstrate that a sterilisation process can consistently and reliably achieve the required level of sterility without adversely affecting the safety, quality or performance of the medical device.
For devices supplied sterile, sterilisation is a critical manufacturing process because the effectiveness of the process cannot normally be fully verified by inspecting or testing every finished device. Instead, manufacturers must establish, validate, control and routinely monitor the sterilisation process to provide objective evidence that it remains effective.
The validation approach will depend on the sterilisation method, device design, materials, packaging system and manufacturing process. Common sterilisation methods for medical devices include:
- Ethylene oxide (EO) sterilisation
- Radiation sterilisation, including gamma, electron beam and X-ray
- Moist heat sterilisation
- Other specialised sterilisation processes where appropriate for the device
Validation typically considers factors such as the initial microbiological contamination or bioburden, sterilisation process parameters, product and load configuration, packaging compatibility, material compatibility, sterilant residuals where applicable, and routine process monitoring.
For many terminally sterilised medical devices, the sterilisation process is established to provide a Sterility Assurance Level (SAL) of 10⁻⁶, meaning a probability of no more than one viable microorganism occurring on one in one million sterilised items.
Medical device sterilisation should therefore not be viewed as an isolated production step. It forms part of a wider validation system incorporating risk management, packaging validation, microbiological controls, quality management and ongoing process monitoring throughout the device lifecycle.
Need an Introduction to Medical Device Validation?
This article focuses on sterilization for medical devices. If you're looking for a complete overview of medical device validation, including cleaning, packaging, sterilization, electrical safety, transport validation and regulatory requirements, read our Complete Guide to Medical Device Validation.
Why Is Medical Device Sterilisation Validation Required?
Manufacturers that place medical devices on the market in a sterile condition must be able to demonstrate that the sterilisation process is effective, reproducible and appropriately controlled. Sterilisation validation provides the objective evidence needed to show that the process consistently achieves its intended result while maintaining the safety and performance of the device.
EU MDR Requirements
Under the EU Medical Device Regulation (EU) 2017/745, devices delivered in a sterile state must be designed, manufactured and packaged using appropriate validated methods.
The General Safety and Performance Requirements in Annex I require devices labelled as sterile to be processed, manufactured, packaged and, where applicable, sterilised using appropriate validated methods.
Sterilisation evidence therefore forms an important part of the manufacturer’s technical documentation and should demonstrate that the selected process is suitable for the device, packaging system and intended sterile claim.
New to the EU Medical Device Regulation?
Sterilisation validation forms part of the wider regulatory requirements for medical devices supplied sterile in the European Union. For a practical introduction to device classification, conformity assessment, technical documentation, clinical evaluation, risk management, post-market surveillance and the General Safety and Performance Requirements, read our MDR for Beginners Guide.
UK MDR Requirements
Medical devices placed on the Great Britain market must comply with the applicable requirements of the UK Medical Devices Regulations 2002 (UK MDR 2002), as amended.
Where a device is supplied sterile, the manufacturer must establish appropriate controls for manufacturing, sterilisation and packaging and maintain evidence supporting the sterile condition of the finished device.
The sterilisation process and supporting validation documentation should therefore form part of the evidence used to demonstrate conformity with the applicable UK requirements.
Placing Medical Devices on the UK Market?
Sterilisation validation is also an important consideration for medical devices supplied sterile in Great Britain. For a practical overview of device classification, UKCA marking, MHRA registration, technical documentation, quality management and the wider regulatory requirements, read our Guide to Regulating Medical Devices in the UK.
ISO 13485 and Process Validation
ISO 13485 requires manufacturers to validate production and service processes where the resulting output cannot be fully verified by subsequent monitoring or measurement.
Sterilisation is a key example of such a process.
The quality management system should therefore establish controls covering areas such as sterilisation validation, equipment qualification, defined process parameters, personnel responsibilities, routine monitoring, records, maintenance, change control and revalidation.
How Does Sterilisation Validation Fit into ISO 13485?
Sterilisation is a critical process that must be appropriately validated and controlled within the medical device quality management system. For a practical overview of process validation, production controls, documentation, change management and other QMS requirements, read our Guide to ISO 13485 for Medical Devices.
Sterilisation and ISO 14971 Risk Management
Sterilisation should also be integrated with the manufacturer’s ISO 14971 risk management process.
Potential risks can include an inadequate sterilisation process, excessive bioburden, incorrect loading configurations, process deviations, packaging failure, sterilisation-induced material degradation and unacceptable sterilant residuals.
The results of risk management should help determine the appropriate validation activities, process controls, acceptance criteria and ongoing monitoring necessary to maintain the validated state throughout the medical device lifecycle.
How Does Risk Management Apply to Sterilisation Validation?
Sterilisation-related hazards should be considered throughout the medical device risk management process, including inadequate sterilisation, excessive bioburden, process deviations, material degradation and packaging failure. For a practical overview of identifying, evaluating and controlling medical device risks, read our Complete Guide to ISO 14971 Medical Device Risk Management.
Choosing the Right Sterilisation Method for a Medical Device
There is no single sterilisation method that is suitable for every medical device. The manufacturer must select and justify a process that can achieve the required sterility assurance while remaining compatible with the device, its materials, packaging system and intended performance.
The decision should be made early in device development because the sterilisation method can influence material selection, product design, packaging, manufacturing processes, biological evaluation and shelf-life validation.
Factors to Consider When Selecting a Sterilisation Method
The selection of an appropriate sterilisation process should consider factors such as:
- Device materials and their sensitivity to heat, moisture, radiation or chemical exposure
- Device geometry, including lumens, joints and other difficult-to-access areas
- Initial product bioburden and microbiological characteristics
- Whether the device can tolerate the temperatures and pressures associated with moist heat
- Potential effects of radiation on polymers, electronics or other materials
- Potential ethylene oxide residuals and the ability of the device to undergo adequate aeration
- Packaging compatibility and maintenance of sterile barrier integrity
- Required shelf life
- Manufacturing volumes and load configurations
- The ability to routinely monitor and control the sterilisation process
The selected method should be supported by documented evidence demonstrating why it is appropriate for the particular device and packaging configuration.
Common Medical Device Sterilisation Methods
Three of the most widely used terminal sterilisation approaches are ethylene oxide (EO), radiation and moist heat.
Ethylene oxide sterilisation is commonly used for devices that cannot tolerate high temperatures or moisture and can be particularly useful for complex devices and products containing heat-sensitive materials.
Radiation sterilisation, including gamma, electron beam and X-ray, can provide an effective terminal sterilisation method without the use of elevated temperatures associated with steam processing. However, the effect of the radiation dose on device materials and performance must be evaluated.
Moist heat sterilisation, commonly performed using saturated steam, is well established and effective where the device and packaging can withstand the required temperature, moisture and pressure conditions.
Other sterilisation technologies may also be appropriate for particular products, but the manufacturer must demonstrate that the chosen process is suitable, validated and appropriately controlled.
Sterilisation Method and Device Compatibility
Achieving microbial inactivation is only one part of sterilisation validation. The process must not cause unacceptable changes to the medical device.
Manufacturers should therefore assess potential effects on characteristics such as mechanical strength, dimensional stability, electrical performance, material properties, appearance, functionality, biocompatibility and packaging integrity.
Where repeated sterilisation is intended, such as for reusable medical devices, the manufacturer must also consider the cumulative effects of the specified number of processing cycles.
The sterilisation method should ultimately provide the required level of sterility without compromising the safety, performance or intended use of the medical device.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Ethylene Oxide (EO) Sterilisation Validation
Ethylene oxide sterilisation is widely used for medical devices that are sensitive to high temperatures, moisture or radiation. Because EO is a gaseous sterilant, it can penetrate many packaging materials and reach areas of complex devices that may be difficult to sterilise using other methods.
Validation of EO sterilisation processes is principally addressed by ISO 11135, which establishes requirements for the development, validation and routine control of an ethylene oxide sterilisation process for medical devices.
How Does Ethylene Oxide Sterilisation Work?
EO sterilisation exposes the medical device to ethylene oxide gas under carefully controlled process conditions. The effectiveness of the cycle depends on a combination of parameters rather than EO concentration alone.
Important parameters can include temperature, relative humidity, EO concentration, exposure time, pressure and load configuration.
Following exposure, devices typically undergo an aeration phase to reduce residual ethylene oxide and its reaction products to acceptable levels before the product is released.
Validating an EO Sterilisation Process
EO validation should provide documented evidence that the defined sterilisation cycle can repeatedly achieve the required microbiological performance for the specified product and load.
Validation typically considers the sterilisation equipment, product and packaging configuration, preconditioning where applicable, cycle parameters, microbiological challenge, loading patterns and aeration conditions.
Equipment and process qualification commonly incorporates Installation Qualification (IQ), Operational Qualification (OQ) and Performance Qualification (PQ) to demonstrate that the equipment is correctly installed, operates within defined limits and can repeatedly deliver the validated process under production conditions.
Product and Load Configuration
The arrangement of products within the sterilisation load can affect temperature, humidity and EO penetration. Manufacturers therefore need to establish and justify representative or worst-case load configurations during validation.
Different device families may sometimes be included within a common validation approach where appropriate, but the rationale for product grouping and identification of the most challenging product should be documented.
Changes to product configuration, packaging, load density or manufacturing arrangements should subsequently be assessed for their potential impact on the validated cycle.
EO Residuals and ISO 10993-7
Ethylene oxide and its reaction products can remain within a medical device following sterilisation. Residual levels must therefore be appropriately evaluated before the device is released for use.
ISO 10993-7 addresses allowable limits for ethylene oxide sterilisation residuals and provides requirements relevant to assessing EO and ethylene chlorohydrin residues.
The required aeration conditions can depend on the materials, device design, packaging and intended patient contact. Residual testing should therefore be representative of the finished sterilised device and its intended use.
How Does Sterilisation Affect Biological Evaluation?
Sterilisation can affect medical device materials and may introduce or alter chemical residues that need to be considered as part of the biological safety assessment. For a practical overview of ISO 10993, biological evaluation planning, chemical characterisation, toxicological assessment and biocompatibility testing, read our Complete Guide to Biological Evaluation of Medical Devices.
Routine Control of EO Sterilisation
Once the EO process has been validated, manufacturers must ensure that routine production remains within the established validated conditions.
This includes monitoring relevant cycle parameters, reviewing sterilisation records, controlling load configurations, managing deviations and ensuring that equipment remains appropriately maintained and calibrated.
Changes that could affect sterilisation effectiveness should be evaluated through the manufacturer’s change-control process to determine whether additional qualification or revalidation is necessary.
Radiation Sterilisation Validation
Radiation sterilisation is widely used for medical devices that can tolerate exposure to ionising radiation. Unlike ethylene oxide sterilisation, the process does not require a gaseous chemical sterilant and can often be performed on devices in their final packaging configuration.
Medical device radiation sterilisation is principally addressed by the ISO 11137 series, which covers the development, validation and routine control of radiation sterilisation processes and the establishment and substantiation of sterilisation doses.
Common radiation technologies include gamma radiation, electron beam (e-beam) and X-ray sterilisation.
How Does Radiation Sterilisation Work?
Ionising radiation damages the DNA and other cellular components of microorganisms, preventing them from reproducing and thereby achieving the required level of microbial inactivation.
The effectiveness of the process is primarily related to the radiation dose absorbed by the product. Manufacturers must therefore establish a sterilisation dose that provides the required sterility assurance while ensuring that the maximum dose received by the product does not adversely affect device safety or performance.
Gamma, Electron Beam and X-Ray Sterilisation
Gamma sterilisation typically uses radiation generated from cobalt-60. It provides high penetration and is widely used for packaged medical devices and relatively dense product loads.
Electron beam sterilisation uses high-energy electrons generated by an accelerator. Processing can be very rapid, although penetration characteristics differ from gamma radiation and must be considered when establishing product and load configurations.
X-ray sterilisation uses high-energy X-rays generated using an accelerator. It can provide greater penetration than electron beam processing and is increasingly used as an alternative radiation sterilisation technology.
The most appropriate technology depends on factors including device materials, product density, packaging, load configuration, manufacturing volumes and the availability of suitable sterilisation facilities.
Establishing the Sterilisation Dose
The sterilisation dose must be established and justified using an appropriate validated methodology.
The ISO 11137 series provides approaches for establishing and substantiating sterilisation doses based on microbiological information, including product bioburden and verification dose studies.
The objective is to demonstrate that the selected sterilisation dose can achieve the required Sterility Assurance Level (SAL) for the product.
A commonly encountered sterilisation dose is 25 kGy, but this should not simply be assumed to be appropriate for every medical device. The required dose should be established and substantiated for the particular product and sterilisation process.
Dose Mapping and Product Loading
Radiation is not necessarily absorbed uniformly throughout a sterilisation load. Product density, orientation, packaging and load configuration can influence the dose received at different locations.
Dose mapping studies are therefore used to identify areas receiving the minimum and maximum absorbed doses within the defined product loading configuration.
This allows the manufacturer to demonstrate that the minimum dose is sufficient to achieve the required sterilisation objective while the maximum dose remains within the limits established for product and material compatibility.
Material Compatibility with Radiation Sterilisation
Radiation exposure can alter some polymers and other device materials. Potential effects can include changes in colour, brittleness, mechanical properties, molecular structure or long-term material performance.
Manufacturers should therefore evaluate the device at the maximum anticipated radiation dose, taking account of potential processing variability and, where relevant, cumulative exposure.
The assessment should also consider whether radiation-induced changes could affect the device’s biological safety, functional performance, packaging integrity or claimed shelf life.
Routine Control of Radiation Sterilisation
Following validation, routine sterilisation cycles must remain within the established processing conditions.
Routine controls can include monitoring delivered dose, controlling product loading configurations, reviewing dosimetry records, maintaining traceability and investigating deviations.
Where the sterilisation dose has been established using a bioburden-based method, ongoing microbiological monitoring and periodic sterilisation dose audits may also be required to confirm that the originally established dose continues to be appropriate.
Moist Heat Sterilisation Validation
Moist heat sterilisation, commonly referred to as steam sterilisation, is one of the most established methods used for sterilising medical devices that can withstand elevated temperatures, moisture and pressure.
Validation and routine control of moist heat sterilisation processes are principally addressed by ISO 17665. The standard provides requirements for developing, validating and controlling moist heat sterilisation processes used for medical devices.
Because steam sterilisation exposes products to relatively demanding environmental conditions, manufacturers must demonstrate both that the required microbiological performance is achieved and that the device and its packaging remain safe and functional following processing.
How Does Moist Heat Sterilisation Work?
Moist heat sterilisation uses saturated steam at controlled temperatures and pressures to inactivate microorganisms.
The effectiveness of the process depends on appropriate steam contact with the surfaces requiring sterilisation and control of parameters such as temperature, pressure, exposure time, steam quality and load configuration.
Air removal is particularly important because trapped air can prevent effective steam penetration and create areas within the load that do not reach the required sterilisation conditions.
Validating a Moist Heat Sterilisation Process
Validation should demonstrate that the defined cycle can consistently deliver the required sterilisation conditions throughout the specified product and load configuration.
The validation programme typically incorporates Installation Qualification (IQ), Operational Qualification (OQ) and Performance Qualification (PQ).
Performance qualification should challenge the process using defined loading configurations and demonstrate that the required physical and microbiological conditions can be achieved reproducibly.
The manufacturer should establish appropriate acceptance criteria before validation and retain documented evidence supporting the validated cycle.
Temperature Distribution and Heat Penetration Studies
Temperature distribution studies are used to demonstrate how conditions are established throughout the sterilisation chamber, while heat penetration studies evaluate the temperatures achieved within or around the product being sterilised.
Potential cold spots and locations that may be difficult to sterilise should be identified and evaluated.
Sensors should be positioned according to a documented rationale so that the validation provides evidence that the most challenging areas of the load receive an adequate sterilisation process.
Product and Packaging Compatibility
Not all medical devices are suitable for moist heat sterilisation. High temperatures and moisture can affect polymers, adhesives, coatings, electronics and other temperature-sensitive components.
The manufacturer should evaluate whether sterilisation could cause changes to characteristics such as:
- Mechanical properties and dimensional stability
- Device functionality and performance
- Material degradation
- Adhesives and bonded components
- Labelling and printed information
- Sterile barrier integrity
- Biological safety
Packaging must also allow the sterilisation process to occur effectively while maintaining the sterile barrier following processing and throughout the claimed shelf life.
Reusable Medical Devices and Repeated Steam Sterilisation
For reusable devices intended to undergo steam sterilisation between uses, validation must consider the effects of repeated processing cycles.
Repeated exposure to cleaning, disinfection and sterilisation can progressively affect device materials, joints, seals, coatings, cutting surfaces and other components.
Validation should therefore support the manufacturer’s specified reprocessing instructions and, where a maximum number of reuse or sterilisation cycles is claimed, provide evidence that the device continues to meet its safety and performance requirements throughout that period.
Routine Control of Moist Heat Sterilisation
Following validation, the sterilisation process must remain within its established validated parameters.
Routine controls can include monitoring cycle time, temperature and pressure; reviewing cycle records; controlling loading patterns; maintaining and calibrating sterilisation equipment; and investigating failed or abnormal cycles.
Changes to the steriliser, cycle parameters, device, packaging or loading configuration should be assessed through change control to determine whether additional qualification or revalidation is required.
Sterility Assurance Level (SAL), Bioburden and Microbiological Control
Sterilisation validation is not simply about running a device through a sterilisation cycle. Manufacturers need to understand and control the microbiological condition of the product before sterilisation and demonstrate that the validated process provides the required level of sterility assurance.
Three concepts are particularly important: Sterility Assurance Level (SAL), bioburden and microbiological control.
What Is a Sterility Assurance Level (SAL)?
Sterility cannot be demonstrated by testing every individual finished device. Instead, sterilisation processes are validated using a probability-based concept known as the Sterility Assurance Level (SAL).
For many terminally sterilised medical devices, an SAL of 10⁻⁶ is used. This represents a probability of no more than one viable microorganism occurring on one in one million sterilised items.
The required SAL should be established as part of the sterilisation strategy and supported by the applicable sterilisation standard and regulatory requirements.
What Is Medical Device Bioburden?
Bioburden is the population of viable microorganisms present on or in a product and/or sterile barrier system before sterilisation.
Bioburden can be introduced through raw materials, components, manufacturing processes, personnel, equipment, water systems, the manufacturing environment and product handling.
Understanding the microbiological condition of the device before sterilisation is therefore an important part of developing and maintaining an effective sterilisation process.
Bioburden Testing and ISO 11737-1
ISO 11737-1 addresses the determination of the population of microorganisms on medical devices, components, raw materials and packages.
A bioburden testing programme may consider the number and nature of microorganisms present, sampling methods, recovery techniques, product families, manufacturing variability and trends over time.
The results can be particularly important where the sterilisation dose or process has been established using microbiological data.
Sterility Testing and ISO 11737-2
ISO 11737-2 addresses tests of sterility performed during the definition, validation and maintenance of a sterilisation process.
An important distinction is that sterility testing alone does not demonstrate that a routine sterilisation process is adequately validated.
Testing examines only the samples selected for evaluation, whereas sterilisation validation provides evidence that the defined process can consistently achieve the required microbiological outcome across the specified product and load.
Controlling Bioburden Before Sterilisation
A validated sterilisation process should not be used as a substitute for appropriate manufacturing hygiene and microbiological control.
Manufacturers should establish suitable controls over factors that can influence product bioburden, including the manufacturing environment, personnel practices, raw materials, components, cleaning processes, equipment and storage conditions.
Unexpected increases or changes in bioburden may indicate a change within the manufacturing process and should be appropriately investigated.
Maintaining Microbiological Control
Microbiological control continues after the initial sterilisation validation.
Manufacturers may need to monitor bioburden trends, review environmental or manufacturing changes, investigate atypical results and periodically confirm that the assumptions used during sterilisation validation remain valid.
This ongoing evidence helps demonstrate that the sterilisation process remains appropriate throughout the medical device lifecycle.
Sterilisation Process Validation: IQ, OQ and PQ
Sterilisation validation must demonstrate more than the effectiveness of a single successful sterilisation cycle. Manufacturers need objective evidence that the sterilisation equipment and process can operate consistently within defined parameters and repeatedly achieve the required outcome.
A typical validation programme therefore incorporates Installation Qualification (IQ), Operational Qualification (OQ) and Performance Qualification (PQ). The exact activities depend on the sterilisation technology and applicable standard, but together these stages establish confidence that the process is suitable for routine production.
Installation Qualification (IQ)
Installation Qualification provides documented evidence that the sterilisation equipment and associated systems have been installed correctly and in accordance with approved specifications.
IQ activities may include verification of:
- Equipment identification and installation
- Utilities and supporting services
- Instrumentation and sensors
- Calibration status
- Software and control systems
- Equipment documentation
- Maintenance requirements
- Safety systems
- Operating procedures
Any supporting equipment that could influence the sterilisation process should also be appropriately considered.
Operational Qualification (OQ)
Operational Qualification demonstrates that the installed equipment can operate as intended throughout its specified operating ranges.
During OQ, critical process parameters are evaluated and challenged to establish that the sterilisation system can consistently deliver the required conditions.
Depending on the sterilisation method, parameters may include temperature, pressure, humidity, sterilant concentration, radiation dose, exposure time or other process-specific variables.
OQ can also help establish operating limits, alarms and other controls needed to maintain the process within its validated range.
Performance Qualification (PQ)
Performance Qualification demonstrates that the sterilisation process can consistently achieve the required outcome when applied to the actual or appropriately representative medical device and defined production load.
PQ should consider the product, packaging, load configuration and process conditions expected during routine manufacturing.
Where appropriate, worst-case or most challenging configurations should be included so that the validation represents the limits of the intended production process.
Multiple successful qualification runs may be required depending on the sterilisation method, applicable standard and validation approach.
Defining Critical Sterilisation Process Parameters
The manufacturer should identify the parameters that can affect sterilisation effectiveness and establish appropriate operating limits and acceptance criteria.
These will vary according to the technology. For example, an EO process may depend on temperature, humidity, EO concentration and exposure time, while a radiation process depends heavily on absorbed dose and a moist heat process requires control of temperature, pressure and exposure conditions.
The relationship between these parameters and the required process outcome should be understood and documented.
Worst-Case Product and Load Configurations
Sterilisation validation should challenge conditions that could make successful sterilisation more difficult.
This may include the most difficult device geometry, highest product density, largest load, challenging packaging configuration or locations within the sterilisation system that are expected to receive the least favourable processing conditions.
The rationale for selecting the worst-case product and load configuration should be documented rather than relying solely on nominal production conditions.
Establishing Acceptance Criteria
Acceptance criteria should be defined in the validation protocol before qualification activities begin.
Criteria may relate to physical process parameters, microbiological results, biological indicators, dosimetry, product performance, packaging integrity or other characteristics relevant to the sterilisation technology.
Where a validation result falls outside the predefined acceptance criteria, the deviation should be investigated and its impact assessed rather than simply repeating the test until a passing result is obtained.
Routine Monitoring and Control of Sterilisation Processes
Completing sterilisation validation does not mean the process can then operate without further oversight. Manufacturers must establish controls to demonstrate that each routine sterilisation cycle remains within the conditions established during validation.
The nature of routine monitoring depends on the sterilisation technology, but the objective is the same: to provide documented evidence that the process remains controlled and that devices released as sterile have been processed in accordance with the validated specification.
Monitoring Critical Process Parameters
Critical sterilisation parameters should be monitored and recorded during routine processing.
Depending on the sterilisation method, this may include parameters such as temperature, pressure, humidity, exposure time, EO concentration, absorbed radiation dose or other process-specific variables.
The recorded parameters should be compared against established acceptance criteria before the sterilised product is released.
Physical, Chemical and Biological Indicators
Different monitoring methods may be used to provide information about sterilisation process performance.
Physical monitoring uses data generated by the sterilisation equipment or associated instrumentation, such as temperature, pressure, time or radiation dose measurements.
Chemical indicators can provide evidence that a package or load has been exposed to particular sterilisation conditions. However, a chemical indicator alone does not demonstrate that the required sterility assurance has been achieved.
Biological indicators contain characterised microorganisms with known resistance to a particular sterilisation process and may be used during validation or routine monitoring where required by the applicable process and standard.
The monitoring strategy should be appropriate to the sterilisation method and validated process.
Sterilisation Batch and Cycle Records
Each sterilisation cycle should be supported by sufficient documentation to demonstrate that it was performed within the approved process specification.
Records may include the steriliser or irradiation facility identification, date and cycle or batch number, product and load configuration, relevant process parameters, monitoring results, deviations and the person responsible for review or release.
Where sterilisation is outsourced, the manufacturer should ensure that appropriate sterilisation records and certificates are obtained and retained as part of the device history.
Product Release Following Sterilisation
Sterile medical devices should only be released after the applicable sterilisation acceptance criteria have been satisfied.
Release may be based on review of physical process records together with other specified monitoring data. Some validated sterilisation processes may use parametric release, where permitted and appropriately established, rather than relying on conventional sterility testing of finished products.
The release procedure should clearly define the evidence that must be reviewed and who has authority to approve the product for release.
Managing Sterilisation Deviations
A sterilisation cycle that falls outside an established process parameter or acceptance criterion should not automatically be accepted or simply reprocessed.
The deviation should be documented and investigated to determine its cause and potential impact on product sterility, packaging, materials and device performance.
Any decision to reprocess a device should itself be supported by evidence that additional exposure will not adversely affect the device or its packaging.
Outsourced Sterilisation Processes
Many manufacturers use specialist external facilities to perform EO, radiation or other terminal sterilisation processes.
Outsourcing sterilisation does not transfer the manufacturer’s responsibility for ensuring that the process is validated and controlled.
The sterilisation provider should therefore be appropriately selected, qualified and monitored. Responsibilities for validation, routine processing, change notification, deviations, record retention and product release should be clearly defined between the manufacturer and sterilisation provider.
Maintaining the Validated State
Routine process data should be reviewed over time to identify trends or changes that could affect sterilisation performance.
Equipment maintenance, calibration, microbiological monitoring, supplier controls, deviations, product changes and process changes should all feed into the ongoing assessment of the validated process.
This ensures that sterilisation validation remains a lifecycle activity rather than a one-time exercise.
Sterilisation and Medical Device Packaging Validation
For medical devices supplied sterile, sterilisation and packaging validation are closely connected. The packaging system must allow the selected sterilisation process to be effective while subsequently maintaining the sterile condition of the device until the package is opened for use.
The final packaging configuration should therefore be considered during sterilisation validation rather than treating packaging as an independent activity.
The Sterile Barrier System
The sterile barrier system (SBS) provides the minimum packaging necessary to prevent the ingress of microorganisms and allow aseptic presentation of the device at the point of use.
The SBS may take different forms depending on the device, including pouches, trays, lids and other packaging configurations.
For terminally sterilised medical devices, the requirements for sterile barrier systems and packaging systems are principally addressed by the ISO 11607 series.
ISO 11607 and Sterilisation
ISO 11607-1 addresses requirements for materials, sterile barrier systems and packaging systems for terminally sterilised medical devices.
ISO 11607-2 addresses validation requirements for the forming, sealing and assembly processes used to manufacture sterile barrier systems and packaging systems.
Together, these requirements help demonstrate that the packaging can withstand the selected sterilisation process and subsequently maintain its protective function throughout the claimed product lifecycle.
Packaging Compatibility with the Sterilisation Method
Different sterilisation technologies place different demands on packaging materials.
EO sterilisation may require packaging that permits appropriate penetration and removal of the sterilant. Radiation can cause changes to certain polymers, adhesives or packaging components. Moist heat exposes packaging to elevated temperature, pressure and moisture.
The manufacturer should therefore demonstrate that the selected packaging materials and configuration are compatible with the sterilisation method under the conditions expected during routine processing.
Seal Strength and Package Integrity
Sterilisation can affect package seals and material properties. Validation should therefore consider whether the process could cause weakening, embrittlement, delamination, distortion or other changes that may compromise the sterile barrier.
Testing may include seal strength, seal integrity and visual inspection, together with other appropriate package performance tests.
The acceptance criteria and test methods should be defined according to the packaging system, identified risks and applicable standards.
Distribution and Transportation After Sterilisation
A sterile package must remain intact after leaving the sterilisation facility.
Manufacturers should therefore consider the stresses that packaged devices may encounter during distribution, including vibration, shock, compression, handling and environmental conditions.
Distribution simulation can be combined with subsequent package integrity testing to demonstrate that the sterile barrier continues to perform after representative transportation stresses.
Shelf Life and Maintaining Sterility
The sterile barrier system must continue to protect the device throughout its claimed shelf life.
Accelerated and real-time ageing studies may therefore be used to evaluate whether packaging materials, seals and sterile barrier integrity remain acceptable over time.
Packaging shelf-life evidence should be considered alongside device stability and performance evidence when establishing the overall expiry date of a sterile medical device.
Testing the Final Sterilised Package
Where sterilisation can influence packaging performance, testing should be conducted on samples representative of the final sterilised packaging configuration.
This helps ensure that the evidence reflects the actual product that will be placed on the market rather than an unsterilised packaging system that has not experienced the validated process.
The overall objective is to demonstrate a continuous chain of protection:
Validated sterilisation process → validated sterile barrier system → controlled distribution and storage → maintenance of sterility until point of use.
How Do You Validate Packaging for Sterile Medical Devices?
Sterilisation validation and packaging validation are closely connected. For devices supplied sterile, manufacturers must demonstrate that the sterile barrier system can withstand the sterilisation process and maintain sterility throughout distribution and shelf life. For a practical overview of ISO 11607, seal integrity, packaging process validation, distribution testing and ageing studies, read our Complete Guide to Medical Device Packaging Validation.
Sterilisation Validation Protocols and Reports
Sterilisation validation should be supported by controlled documentation that clearly defines what will be validated, how the validation will be performed, the acceptance criteria that must be achieved and the evidence demonstrating that the process was successful.
A well-structured validation package provides traceable evidence that the sterilisation process has been appropriately established and can be maintained in a validated state during routine production.
Sterilisation Validation Protocol
The validation protocol should be approved before validation activities begin and should define the planned approach to the study.
Depending on the sterilisation method and applicable standard, the protocol may include:
- Purpose and scope of the validation
- Device and product family identification
- Sterilisation method and equipment
- Packaging and load configuration
- Responsibilities of the manufacturer and sterilisation provider
- Applicable standards and procedures
- Critical process parameters
- IQ, OQ and PQ activities
- Microbiological requirements
- Sampling plans
- Test methods
- Worst-case configurations
- Acceptance criteria
- Handling of deviations
- Required records and approvals
The protocol should provide sufficient detail for the validation to be performed consistently and for the results to be objectively assessed against predefined criteria.
Defining Worst-Case Conditions
A sterilisation validation should appropriately represent the most challenging conditions expected during routine manufacture.
Worst-case conditions will depend on the sterilisation technology and may relate to device geometry, packaging, product density, load configuration, bioburden, sterilant penetration, absorbed radiation dose or heat penetration.
Where several products are included within the same sterilisation validation, the manufacturer should document why the selected representative product provides an appropriate challenge for the wider product family.
Sterilisation Validation Report
Following completion of the validation activities, the results should be documented within a validation report.
The report should describe the work performed, present and evaluate the results, identify any deviations and conclude whether the predefined acceptance criteria were achieved.
It should also clearly identify the validated process parameters, product and packaging configurations and any limitations or conditions associated with the validation.
Managing Validation Deviations
Any deviation from the approved protocol or predefined acceptance criteria should be documented and investigated.
The investigation should consider the potential effect on the validity of the study and whether additional testing, corrective action or repetition of part of the validation is necessary.
A failed result should not simply be excluded or repeatedly tested until an acceptable result is obtained without an appropriate documented investigation.
Sterilisation Product Families
It may be possible to include multiple devices within a common sterilisation validation where they have sufficiently similar characteristics and a scientifically justified product-family approach can be established.
The manufacturer should consider characteristics that could influence sterilisation effectiveness, such as materials, device geometry, dimensions, packaging, manufacturing processes and microbiological characteristics.
The rationale for selecting a representative or master product should demonstrate that it presents an appropriate challenge to the sterilisation process.
Maintaining Traceability
Sterilisation validation documentation should provide clear traceability between the device, sterilisation specification, validation protocol, test results, validation report and routine sterilisation records.
Changes to the device, packaging, manufacturing process, sterilisation provider or sterilisation parameters should also be traceable so that their potential impact on the validated process can be assessed.
This documentation ultimately provides the evidence needed to demonstrate that the sterilisation process has been defined, validated, controlled and maintained throughout the device lifecycle.
When Is Sterilisation Revalidation Required?
Sterilisation validation is not necessarily a one-time activity. Manufacturers should periodically review the validated process and assess changes that could affect its ability to consistently achieve the required sterilisation outcome.
Revalidation may involve repeating the complete validation or performing targeted studies, depending on the nature of the change, the sterilisation method, applicable standard and associated risk.
Changes to the Medical Device
Changes to the device may affect how effectively it can be sterilised.
Examples include changes to materials, dimensions, geometry, internal channels or lumens, components, surface characteristics or product configuration.
The manufacturer should assess whether the change affects the assumptions established during the original validation and determine whether additional validation evidence is required.
Changes to the Packaging System
Changes to sterile barrier materials, pouch or tray dimensions, seals, adhesives, packaging configuration or packaging suppliers may affect sterilant penetration, heat transfer, radiation dose or maintenance of sterility.
Packaging changes should therefore be assessed for their potential impact on both the sterilisation validation and packaging validation.
Changes to the Sterilisation Process
Changes to validated process parameters may require further assessment or revalidation.
These could include changes to cycle parameters, exposure time, temperature, humidity, EO concentration, radiation dose, equipment, load configuration or other process-specific conditions.
A manufacturer should not assume that a modified process remains covered by the original validation without documented justification.
Changes to the Manufacturing Process
Manufacturing changes can alter the microbiological condition of a device before sterilisation.
Changes to manufacturing locations, equipment, cleaning processes, environmental controls, raw materials, suppliers or product handling may therefore affect bioburden or other characteristics relevant to sterilisation.
These changes should be assessed through the manufacturer’s change-control and risk-management processes.
Changes to the Sterilisation Facility or Provider
Where sterilisation is outsourced, changes made by the sterilisation provider may also affect the validated process.
This could include relocation to another facility, use of different sterilisation equipment, significant equipment modifications or changes to established processing conditions.
Quality agreements with external sterilisation providers should define appropriate change-notification requirements so that the manufacturer can assess the impact before affected product is released.
Periodic Review and Requalification
Even where no significant change has occurred, the sterilisation process should be reviewed at appropriate intervals in accordance with the applicable sterilisation standard and established procedures.
The review may consider routine processing data, deviations, equipment performance, calibration and maintenance records, microbiological trends, product changes and previous requalification results.
Where the review identifies uncertainty about the continued effectiveness of the process, additional qualification or revalidation may be necessary.
A Risk-Based Approach to Revalidation
Not every change requires repetition of the entire sterilisation validation.
The manufacturer should assess the nature and significance of the change, determine whether it could affect the validated process and document the rationale for the resulting action.
Depending on the outcome, this may range from a documented assessment demonstrating that the existing validation remains applicable through to targeted testing, partial requalification or complete revalidation of the sterilisation process.
Sterilisation Validation in Medical Device Technical Documentation
For a medical device supplied sterile, the technical documentation should contain sufficient evidence to demonstrate that the sterilisation process has been appropriately selected, validated, controlled and maintained.
Sterilisation documentation should not sit in isolation. It should connect with the device description, manufacturing information, risk management, biological evaluation, packaging validation, shelf-life evidence and the manufacturer’s quality management system.
Sterilisation Method and Rationale
The technical documentation should clearly identify the sterilisation method used for the finished device and explain why it is appropriate for the product.
The rationale should consider the device design, materials, intended use, packaging system and compatibility with the selected sterilisation technology.
Where relevant, alternative sterilisation methods considered during development and the reasons for their rejection may also form part of the design and risk-management evidence.
Sterilisation Process Specification
The validated sterilisation process should be clearly defined.
Depending on the method, this may include parameters such as exposure time, temperature, pressure, humidity, EO concentration, radiation dose, load configuration and other conditions necessary to achieve the required process outcome.
The specification should be consistent with the conditions established during validation and subsequently used for routine processing.
Evidence of Sterilisation Validation
The technical documentation should reference or contain the appropriate validation evidence demonstrating that the sterilisation process is capable of consistently achieving its specified requirements.
This may include validation protocols and reports, IQ/OQ/PQ documentation, microbiological studies, dose establishment or dose mapping studies, biological or chemical indicator data and other method-specific evidence.
Where sterilisation is outsourced, relevant evidence from the external sterilisation provider should be appropriately controlled and available to the manufacturer.
Microbiological Evidence
Relevant microbiological evidence should demonstrate how the microbiological condition of the product is understood and controlled.
Depending on the sterilisation method, this may include bioburden data, microbiological monitoring, tests of sterility performed as part of process definition or validation, and evidence supporting the selected sterilisation approach.
The evidence should be consistent with the assumptions and acceptance criteria used during sterilisation validation.
Packaging and Shelf-Life Evidence
For devices supplied sterile, the technical documentation should also demonstrate that the sterile barrier system remains suitable following sterilisation.
This may include packaging validation, seal integrity testing, distribution testing, accelerated and real-time ageing studies and evidence that the sterile barrier can maintain sterility throughout the claimed shelf life.
The sterilisation, packaging and shelf-life evidence should therefore support one another rather than being treated as unrelated validation activities.
Biological Evaluation and Sterilisation Residuals
The effect of sterilisation on biological safety should be considered within the device’s biological evaluation.
Sterilisation may alter materials or create degradation products, while certain processes can introduce residues that require specific assessment. For example, devices sterilised using ethylene oxide may require evaluation of EO-related residuals in accordance with the applicable requirements of ISO 10993-7.
Testing should therefore be representative of the finished device in its final processed condition, where appropriate to the biological evaluation strategy.
Linking Sterilisation to Risk Management
Sterilisation-related hazards and foreseeable failures should be addressed within the device risk-management process.
This may include risks associated with inadequate sterilisation, excessive bioburden, process deviations, sterilisation residuals, material degradation, packaging failure and loss of sterile barrier integrity.
The risk-management documentation should demonstrate how these risks are controlled and how the associated verification and validation evidence confirms the effectiveness of those controls.
Keeping Technical Documentation Current
Sterilisation documentation should remain current throughout the medical device lifecycle.
Changes to the device, packaging, manufacturing process, sterilisation parameters, equipment or sterilisation provider should be assessed to determine whether existing validation evidence remains applicable.
This creates traceability between design and manufacturing controls, risk management, sterilisation validation, packaging validation and the finished sterile medical device placed on the market.
Is Your MDR Technical File Ready for Notified Body Review?
Sterilisation validation is an important part of the verification and validation evidence for medical devices supplied sterile. For practical guidance on structuring your technical documentation, linking validation evidence, avoiding common deficiencies and preparing for regulatory review, read our Guide to Building a Strong MDR Technical File.
Common Medical Device Sterilisation Validation Mistakes
Sterilisation validation involves the interaction of the device, manufacturing process, microbiological condition, packaging system and selected sterilisation technology. Weaknesses in any of these areas can undermine the overall validation strategy.
Some of the most common problems occur when manufacturers treat sterilisation as a standalone manufacturing activity rather than a controlled process that must remain linked to the device throughout its lifecycle.
Selecting the Sterilisation Method Too Late
The sterilisation method should be considered during device development rather than after the design has been finalised.
Materials, components, electronics, adhesives and packaging may respond differently to EO, radiation or moist heat. Selecting a method late in development can therefore result in compatibility problems, additional testing or even changes to the device or packaging.
Failing to Validate Worst-Case Conditions
Testing only a typical device or nominal load may not adequately challenge the sterilisation process.
Validation should consider the configurations most difficult to sterilise, such as challenging device geometries, dense loads, difficult-to-penetrate packaging or other conditions that could affect sterilant penetration, radiation dose or heat transfer.
Treating Sterility Testing as Sterilisation Validation
Finished-product sterility testing alone does not demonstrate that a sterilisation process is validated.
Sterilisation is controlled through the development, validation and routine control of the process. Testing a sample of finished devices cannot provide the same evidence that the defined process consistently achieves its required outcome.
Ignoring Bioburden and Manufacturing Controls
A sterilisation cycle should not compensate for poorly controlled manufacturing conditions.
Changes in raw materials, manufacturing environments, cleaning, handling or production processes can affect product bioburden and potentially challenge assumptions made during the original sterilisation validation.
Overlooking Packaging Compatibility
A device may be successfully sterilised while its sterile barrier system is adversely affected by the process.
Packaging materials, seals and adhesives should therefore be evaluated following exposure to the selected sterilisation process and through appropriate packaging, ageing and distribution validation.
Poor Control of Outsourced Sterilisation
Using a contract sterilisation provider does not remove the medical device manufacturer’s responsibility for the validated process.
Responsibilities for validation, routine processing, deviations, change notification, documentation and release should be clearly established and controlled between the manufacturer and sterilisation provider.
Failing to Assess Changes and Revalidation
A sterilisation validation cannot simply be completed and then assumed to remain applicable indefinitely.
Changes to the device, materials, packaging, manufacturing process, load configuration, sterilisation equipment or process parameters should be assessed through change control to determine whether requalification or revalidation is required.
Using Outdated Sterilisation Standards
Manufacturers should ensure that their validation strategy reflects the applicable and current standards for the selected sterilisation method.
This is particularly important when standards are revised. For example, ISO 17665:2024 is now the current standard for moist heat sterilisation, while ISO 11137-1:2025 is the current edition covering development, validation and routine control of radiation sterilisation processes.
Ultimately, a strong sterilisation validation programme should demonstrate not only that a sterilisation cycle worked during the original study, but that the device, process and packaging remain appropriately controlled throughout the product lifecycle.
How Patient Guard Can Help with Sterilisation Validation
Sterilisation validation can involve multiple standards, specialist testing laboratories and contract sterilisation providers. Patient Guard can help medical device manufacturers develop a clear validation strategy and ensure that the resulting evidence supports the wider regulatory and technical documentation.
Our regulatory and quality specialists can support manufacturers with:
- Developing and reviewing sterilisation validation strategies
- Identifying applicable sterilisation standards and regulatory requirements
- Reviewing sterilisation validation protocols and reports
- Supporting IQ, OQ and PQ planning and documentation
- Defining worst-case devices, product families and load configurations
- Reviewing bioburden and microbiological control requirements
- Supporting EO, radiation and moist heat sterilisation validation
- Reviewing EO residual requirements and links to biological evaluation
- Assessing sterilisation and packaging compatibility
- Linking sterilisation evidence with ISO 11607 packaging validation
- Reviewing outsourced sterilisation documentation
- Assessing changes and revalidation requirements
- Integrating sterilisation evidence into EU MDR and UK medical device technical documentation
- Supporting ISO 13485 quality management and risk management requirements
Whether you are developing a new sterile medical device, transferring an existing sterilisation process, responding to a Notified Body finding or reviewing an established validation programme, Patient Guard can help identify the evidence required and develop a proportionate route to compliance.
Medical Device Sterilisation Validation FAQs
Medical device sterilisation validation is the documented process used to demonstrate that a sterilisation process can consistently achieve its specified requirements when applied to a defined medical device, packaging system and load configuration.
Validation typically includes qualification of the equipment and process, microbiological considerations, defined acceptance criteria, routine monitoring and ongoing review to ensure the process remains in a validated state.
For many terminally sterilised medical devices, a Sterility Assurance Level (SAL) of 10⁻⁶ is used. This represents a probability of no more than one viable microorganism occurring on one in one million sterilised items.
The appropriate SAL should be determined and justified according to the device, sterilisation method and applicable regulatory and standards requirements.
The applicable standard depends on the sterilisation method. Key standards include ISO 11135 for ethylene oxide sterilisation, the ISO 11137 series for radiation sterilisation and ISO 17665 for moist heat sterilisation.
Other relevant standards may include the ISO 11737 series for microbiological methods, ISO 10993-7 for ethylene oxide residuals and ISO 11607 for packaging of terminally sterilised medical devices.
Installation Qualification (IQ) demonstrates that sterilisation equipment has been correctly installed. Operational Qualification (OQ) demonstrates that the equipment can operate within its defined operating ranges. Performance Qualification (PQ) demonstrates that the process can consistently achieve the required outcome when applied to the actual or appropriately representative product and load.
Together, IQ, OQ and PQ provide structured evidence supporting the validated sterilisation process.
Bioburden testing determines the viable microorganisms present on or in a device before sterilisation and can be used to understand and monitor microbiological control.
Tests of sterility may be used for specific purposes during the definition, validation and maintenance of a sterilisation process. However, testing samples for sterility does not replace validation of the sterilisation process.
Sterilisation and packaging validation are closely related for devices supplied sterile. The sterile barrier system must be compatible with the selected sterilisation process and subsequently maintain sterility throughout handling, distribution, storage and the claimed shelf life.
Packaging requirements for terminally sterilised medical devices are principally addressed through the ISO 11607 series.
Yes. Medical device manufacturers commonly use specialist providers for processes such as EO and radiation sterilisation.
However, outsourcing the physical sterilisation process does not remove the manufacturer’s responsibility for ensuring that the process is appropriately validated and controlled. Responsibilities for validation, routine processing, deviations, changes, documentation and product release should be clearly established.
Revalidation may be required when a change could affect the established sterilisation process. Examples include changes to the device, materials, packaging, manufacturing process, load configuration, sterilisation parameters, equipment or sterilisation facility.
The manufacturer should assess changes through its change-control and risk-management processes to determine whether no additional validation, targeted testing, partial requalification or more extensive revalidation is required.
References
This guide is based on applicable medical device regulations and international standards relating to sterilisation validation, microbiological control, sterile barrier systems and the development, validation and routine control of sterilisation processes for medical devices.
| Organisation | Reference | Why it's relevant |
|---|---|---|
| European Union | Regulation (EU) 2017/745 (EU MDR) | Establishes regulatory requirements for medical devices placed on the EU market, including requirements relating to devices supplied sterile, manufacturing processes, risk management and verification and validation evidence. |
| UK Government | UK Medical Devices Regulations 2002 (as amended) | Establishes the regulatory framework for medical devices placed on the Great Britain market, including applicable requirements for devices supplied in a sterile condition. |
| ISO | ISO 11135:2014 – Ethylene Oxide Sterilisation | Specifies requirements for the development, validation and routine control of ethylene oxide sterilisation processes for medical devices. |
| ISO | ISO 11137-1:2025 – Radiation Sterilisation | Specifies requirements for the development, validation and routine control of radiation sterilisation processes for medical devices. |
| ISO | ISO 11137-2:2013 – Establishing the Sterilisation Dose | Specifies methods for establishing the radiation sterilisation dose, substantiating selected doses and performing sterilisation dose audits. Amendment 1:2022 also applies. |
| ISO | ISO 17665:2024 – Moist Heat Sterilisation | Specifies requirements for the development, validation and routine control of moist heat sterilisation processes for medical devices. |
| ISO | ISO 11737-1:2018 – Bioburden Determination | Specifies requirements and guidance for determining and characterising populations of viable microorganisms on or in healthcare products, components, raw materials and packages. |
| ISO | ISO 11737-2:2019 – Tests of Sterility | Specifies criteria for tests of sterility performed during the definition, validation and maintenance of a sterilisation process. |
| ISO | ISO 10993-7:2026 – Ethylene Oxide Sterilisation Residuals | Specifies allowable limits for residual ethylene oxide and ethylene chlorohydrin in applicable EO-sterilised medical devices and methods for determining conformity. |
| ISO | ISO 11607-1:2019 – Packaging for Terminally Sterilised Medical Devices | Specifies requirements for materials, sterile barrier systems and packaging systems intended to maintain the sterility of terminally sterilised medical devices until the point of use. |
| ISO | ISO 11607-2:2019 – Packaging Process Validation | Specifies validation requirements for forming, sealing and assembly processes used for packaging terminally sterilised medical devices. |
Sterilisation validation should not be treated as a one-time exercise. Manufacturers should maintain the validated state throughout the medical device lifecycle and assess changes to the device, packaging, manufacturing process, sterilisation equipment, load configuration and process parameters to determine whether additional qualification or revalidation is required.
Patient Guards Recent Posts
FDA Medical Device Classification: Class I, Class II and Class III Explained
Does your medical device require FDA 510(k) clearance? This step-by-step guide explains the 510(k) process, substantial equivalence, predicate devices, testing, eSTAR submissions, FDA review and what manufacturers need to do after clearance.
FDA 510(k) Clearance: A Step-by-Step Guide for Medical Device Manufacturers
Does your medical device require FDA 510(k) clearance? This step-by-step guide explains the 510(k) process, substantial equivalence, predicate devices, testing, eSTAR submissions, FDA review and what manufacturers need to do after clearance.
FDA Medical Device Regulations: A Complete Guide for Manufacturers
Planning to place a medical device on the US market? This complete guide explains FDA medical device regulations, including device classification, 510(k), De Novo and PMA pathways, QMSR and ISO 13485, establishment registration, device listing, U.S. Agent requirements, UDI and post-market obligations.
Patient Guards Related Services
Patient Guards Regulatory Tools
Need Training?
Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.
